ArticleGenome medicine2021
The identification of novel immunogenic antigens as potential Shigella vaccine components.
Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Effects of improved water, sanitation, handwashing, and nutrition on early childhood IgG immune repertoire development againstmSphere · 2026Trial
- Development and evaluation of a dual-target glycoconjugate againstFrontiers in immunology · 2026Article
- Asiatic acid, a novel ciprofloxacin adjuvant inhibitsGut microbes · 2025Article
- Effects of improved water, sanitation, handwashing and nutrition on early childhood IgG immune repertoire development againstmedRxiv : the preprint server for health sciences · 2025Article
- Recent Advances in Bioconjugate Vaccine Development.Vaccines · 2025Review
- Genome-wide investigation of outer membrane protein families under mosaic evolution inApplied and environmental microbiology · 2025Article
- Protein-specific immune response elicited by themSphere · 2025Article
- Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.Nature reviews. Microbiology · 2025Review
- Development and Characterization of a Polyvalent Polyclonal Antibody as a Common Capture Antibody for the Detection of Enterotoxigenic Escherichia coli in a Sandwich ELISA.Current microbiology · 2025Article
- A descriptor-free machine learning framework to improve antigen discovery for bacterial pathogens.PloS one · 2025Article
- Investigation of the vaccine potential of anVaccine: X · 2024Article
- Aptamers: A Cutting-Edge Approach for Gram-Negative Bacterial Pathogen Identification.International journal of molecular sciences · 2024Review
- Article
- YfiB: An Outer Membrane Protein Involved in the Virulence ofMicroorganisms · 2022Article
- Recent Progress inPathogens (Basel, Switzerland) · 2021Review
- The identification of novel immunogenic antigens as potential Shigella vaccine components.Genome medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundShigella is a major diarrheal pathogen for which there is presently no vaccine. Whole genome sequencing provides the ability to predict and derive novel antigens for use as vaccines. Here, we aimed to identify novel immunogenic Shigella antigens that could serve as Shigella vaccine candidates, either alone, or when conjugated to Shigella O-antigen.
methodsUsing a reverse vaccinology approach, where genomic analysis informed the Shigella immunome via an antigen microarray, we aimed to identify novel immunogenic Shigella antigens. A core genome analysis of Shigella species, pathogenic and non-pathogenic Escherichia coli, led to the selection of 234 predicted immunogenic Shigella antigens. These antigens were expressed and probed with acute and convalescent serum from microbiologically confirmed Shigella infections.
resultsSeveral Shigella antigens displayed IgG and IgA seroconversion, with no difference in sero-reactivity across by sex or age. IgG sero-reactivity to key Shigella antigens was observed at birth, indicating transplacental antibody transfer. Six antigens (FepA, EmrK, FhuA, MdtA, NlpB, and CjrA) were identified in in vivo testing as capable of producing binding IgG and complement-mediated bactericidal antibody.
conclusionsThese findings provide six novel immunogenic Shigella proteins that could serve as candidate vaccine antigens, species-specific carrier proteins, or targeted adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.